Proteomics International Laboratories (ASX:PIQ) said it developed and released a next-generation PromarkerD test system, an immunoassay-based diagnostic for the prediction of kidney function decline in adults with type 2 diabetes, according to a Monday Australian bourse filing.
The test can identify individuals at risk of diabetes-related chronic kidney disease up to four years before clinical symptoms appear, per the filing. It measures two plasma protein biomarkers, ApoA4 and CD5L, alongside age and estimated glomerular filtration rate to generate a personalized risk score.
The test identified 86% of at-risk individuals, missed by the current standard-of-care estimated glomerular filtration rate and urinary albumin-to-creatinine ratio tests. In a clinical study with 948 participants, the test showed that the high-risk PromarkerD group demonstrated 44-fold greater odds of kidney decline compared with the low-risk group.
The firm's shares fell 6% in recent trading, reaching their lowest point in over five years.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。